ATE194495T1 - T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose - Google Patents

T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose

Info

Publication number
ATE194495T1
ATE194495T1 AT93907942T AT93907942T ATE194495T1 AT E194495 T1 ATE194495 T1 AT E194495T1 AT 93907942 T AT93907942 T AT 93907942T AT 93907942 T AT93907942 T AT 93907942T AT E194495 T1 ATE194495 T1 AT E194495T1
Authority
AT
Austria
Prior art keywords
absent
thr
ser
gly
treatment
Prior art date
Application number
AT93907942T
Other languages
English (en)
Inventor
Anders Joergen Andersen
Roger Aston
Peter Louis Carlen
Penelope Reed Doob
Douglas Kevin Macfadden
David James Phipps
Deborah Rathjen
Fred Widmer
Original Assignee
Advanced Immunit T Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK92645A external-priority patent/DK64592D0/da
Application filed by Advanced Immunit T Inc filed Critical Advanced Immunit T Inc
Application granted granted Critical
Publication of ATE194495T1 publication Critical patent/ATE194495T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93907942T 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose ATE194495T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85883292A 1992-03-27 1992-03-27
DK92645A DK64592D0 (da) 1992-05-14 1992-05-14 Peptider til terapeutisk behandling
US91511892A 1992-07-17 1992-07-17
US98767492A 1992-12-09 1992-12-09
PCT/GB1993/000649 WO1993020102A1 (en) 1992-03-27 1993-03-29 Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE194495T1 true ATE194495T1 (de) 2000-07-15

Family

ID=27439352

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93907942T ATE194495T1 (de) 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose
AT99101349T ATE267838T1 (de) 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschlies slich der multiplen sklerose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99101349T ATE267838T1 (de) 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschlies slich der multiplen sklerose

Country Status (12)

Country Link
EP (2) EP0960886B1 (de)
JP (1) JP3520084B2 (de)
KR (1) KR100312300B1 (de)
AT (2) ATE194495T1 (de)
AU (3) AU684713B2 (de)
CA (1) CA2132516A1 (de)
DE (2) DE69329023T2 (de)
DK (2) DK0635027T3 (de)
ES (2) ES2222625T3 (de)
PT (1) PT960886E (de)
UA (1) UA41881C2 (de)
WO (1) WO1993020102A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
AU697847B2 (en) * 1993-09-24 1998-10-15 Advanced Immunit, Inc. Method for the treatment or prevention of eczema/dermatitis
DE69433817T2 (de) * 1993-09-24 2005-07-14 Advanced Immuni T, Inc. Lineare und cyklische peptide zur behandlung oder vorbeugung der crohn'schen krankheit und/oder der ulzerativen kolitis
EP1242109A4 (de) * 1999-11-09 2004-06-02 Advanced Immunit Inc Verfahren zur behandlung von viuruserkrankungen und anderen störungen durch veränderung der "immediate gene expression" durch verabreichung von peptid t
JP4611233B2 (ja) * 2005-04-06 2011-01-12 ニッタ株式会社 歩行訓練支援装置
US20140322251A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions
EP2832373B1 (de) * 2013-08-02 2017-04-12 Experimentelle Pharmakologie & Onkologie Berlin Buch Liposom zur Blockierung eines standortspezifischen chemokinassoziierten entzündlichen Prozesses bei Gefäßerkrankungen und Metastasen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7544987A (en) * 1986-06-03 1988-01-11 Pert, C.B. Small peptides which inhibit binding to t-4 receptors
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
WO1988009338A1 (en) * 1987-05-22 1988-12-01 Syntbiotech, Inc. Synthetic peptides and a method of treating aids
ATE168698T1 (de) * 1988-05-27 1998-08-15 Us Health Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
US5189022A (en) * 1988-05-27 1993-02-23 The United States Of America As Represented By The Secretary Of Health And Human Services Composition for the treatment of chronic fatigue syndrome

Also Published As

Publication number Publication date
JPH07507061A (ja) 1995-08-03
AU725680B2 (en) 2000-10-19
UA41881C2 (uk) 2001-10-15
DK0960886T3 (da) 2004-09-27
EP0635027A1 (de) 1995-01-25
ATE267838T1 (de) 2004-06-15
EP0960886B1 (de) 2004-05-26
EP0635027B1 (de) 2000-07-12
EP0960886A1 (de) 1999-12-01
JP3520084B2 (ja) 2004-04-19
CA2132516A1 (en) 1993-10-14
PT960886E (pt) 2004-10-29
DK0635027T3 (da) 2000-10-02
KR950700931A (ko) 1995-02-20
AU718442B2 (en) 2000-04-13
ES2149203T3 (es) 2000-11-01
ES2222625T3 (es) 2005-02-01
WO1993020102A1 (en) 1993-10-14
DE69333537T2 (de) 2005-06-16
AU684713B2 (en) 1998-01-08
AU3895393A (en) 1993-11-08
AU2254999A (en) 1999-05-20
AU6354298A (en) 1998-06-18
DE69329023D1 (de) 2000-08-17
KR100312300B1 (ko) 2002-03-20
DE69329023T2 (de) 2001-03-22
DE69333537D1 (de) 2004-07-01

Similar Documents

Publication Publication Date Title
ATE238345T1 (de) Protegrine
ATE209215T1 (de) Protegrine
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
SE9100799L (sv) Rekombinant derivat av human faktor viii
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
ATE171712T1 (de) Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten
RU94046091A (ru) Полипептидные антагонисты бомбезина, фармацевтическая композиция и способ лечения
ES2070635T3 (es) Peptidos para tratamiento.
DE69333537D1 (de) T-peptid und damit verwandte Peptide in der Behandlung von entzündungen einschlies slich der Multiplen Sklerose
ATE287963T1 (de) Pseudomonas exotoxin - myelin basisches protein chimäre proteine
CA2006087A1 (en) Polypeptides isolated from the venom of the spider hololena curta
RU94027578A (ru) Фармацевтическая композиция и способ лечения рассеянного склероза
ATE3773T1 (de) An peptide polymerisationsprodukte gebundene muramyl-peptide und sie enthaltende pharmazeutische zusammensetzungen.
ATE308617T1 (de) Rantes mutanten und deren therapeutischen anwendungen
CA2102606A1 (en) Compositions for the treatment of chronic fatigue syndrome
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
Carrell et al. Structural mobility of antithrombin and its modulation by heparin
ATE120758T1 (de) Peptide, deren verwendung als hemmer gegen entwicklung von t-lymphocyten und wirksamkeit von makrophagen und verfahren zu deren herstellung.
RU94046096A (ru) Линейные или циклические пептиды, их применение, способы лечения и конъюгаты пептидов
DE68905097D1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
RU94036002A (ru) Ингибитор протеазы, днк, вектор, клетка, способ получения ингибитора, фармацевтическая композиция

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee